Trial Profile

Phase 3 clinical trial of INOpulse® for the treatment of fibrotic interstitial lung disease (fILD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitric oxide (Primary)
Indications Interstitial lung diseases; Pulmonary fibrosis
Focus Registrational; Therapeutic Use

Most Recent Events

15 Feb 2023 New trial record
09 Feb 2023 According to a Bellerophon Therapeutics media release, this trial will be conducted in collaboration with Bellerophon's regional partner, Baylor BioScience.
09 Feb 2023 According to a Bellerophon Therapeutics media release, the company announced the clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) to conduct this trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease (fILD) in China.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com